DAVITA Inc. (DVA): Canvas du modèle commercial [Jan-2025 Mis à jour]

Dans le paysage complexe des services de santé, Davita Inc. apparaît comme une force pionnière dans les soins rénaux, transformant la vie des patients luttant contre les maladies rénales chroniques grâce à un modèle commercial innovant et complet. En intégrant de manière transparente les technologies médicales avancées, les soins personnalisés pour les patients et les partenariats stratégiques, Davita a révolutionné le traitement de la dialyse, offrant de l'espoir et des solutions de haute qualité à des milliers de personnes aux prises avec une maladie rénale terminale. Cette toile de modèle commercial complexe révèle le plan stratégique derrière le succès remarquable de Davita dans la prestation de services de santé de pointe qui vont bien au-delà du traitement médical traditionnel.

DAVITA Inc. (DVA) - Modèle d'entreprise: partenariats clés

Fournisseurs de soins de santé et hôpitaux

Depuis 2024, Davita exploite 2 824 centres de dialyse aux États-Unis. Les statistiques clés du partenariat comprennent:

Type de partenariat	Nombre de partenariats	Pourcentage de couverture
Réseaux de référence à l'hôpital	387 principaux systèmes hospitaliers	68% des références potentielles sur les patients en dialyse
Pratiques de néphrologie indépendantes	1 246 pratiques contractuelles	52% de pénétration du marché régional

Fabricants d'équipements médicaux

Les partenariats d'équipement médical de Davita comprennent:

• Fresenius Medical Care (Fournisseur de machines de dialyse primaire)
• Baxter International (dialyse consommables)
• Nikkiso Medical (Dialyse Machine Technology)

Partenaires d'assurance et de couverture

Type de partenariat	Valeur du contrat annuel	Couverture des patients
Médicament	3,2 milliards de dollars	71% de la base de patients en dialyse
Medicaid	1,7 milliard de dollars	22% de la base de patients en dialyse
Assurance privée	1,5 milliard de dollars	7% de la base de patients en dialyse

Partenariats pharmaceutiques

Collaborations pharmaceutiques clés:

• Amgen (médicament EPO)
• Sanofi (liants au phosphate)
• Keryx biopharmaceuticals (suppléments en fer)

Partenariats des fournisseurs technologiques

Fournisseur	Focus technologique	Investissement annuel
Systèmes épiques	Dossiers de santé électroniques	42 millions de dollars
Cerner Corporation	Systèmes de gestion des patients	35 millions de dollars
IBM Watson Health	Analytique des soins de santé AI	28 millions de dollars

DAVITA Inc. (DVA) - Modèle d'entreprise: activités clés

Traitement de dialyse rénale et services de soins aux patients

Davita exploite 2 836 centres de dialyse à travers les États-Unis au quatrième trimestre 2023. La société fournit des services de dialyse rénale à environ 204 000 patients à l'échelle nationale.

Catégorie de service	Volume annuel	Patient à portée de patient
Hémodialyse dans le centre	68,4 millions de traitements de patients	Environ 155 000 patients
Dialyse de la maison	8,6 millions de traitements de patients	Environ 49 000 patients

Programmes de gestion des maladies rénales chroniques

Les programmes de gestion des maladies rénales de Davita se concentrent sur les soins complets des patients et les stratégies d'intervention précoce.

• Réseau de médecins en néphrologie de 3 200 praticiens
• Coordination des soins intégrés pour les patients atteints d'une maladie rénale terminale
• Plans de traitement personnalisés pour la progression de la maladie rénale chronique

Opérations du centre de dialyse et traitement des patients

Davita maintient une infrastructure opérationnelle robuste pour la livraison de traitement de dialyse.

Métrique opérationnelle	Données quantitatives
Centres de dialyse totaux	2 836 centres
Couverture géographique	50 États aux États-Unis
Temps de traitement moyen des patients	3,5-4 heures par session

Recherche médicale et innovation clinique

Davita investit dans la recherche et le développement pour améliorer les méthodologies de traitement des maladies rénales.

• Investissement annuel de R&D: 78,4 millions de dollars en 2022
• Collaboration avec 12 établissements de recherche médicale académique
• Concentrez-vous sur les technologies avancées de dialyse et les protocoles de soins aux patients

Services d'éducation et de soutien aux patients

Davita fournit un soutien complet aux patients via plusieurs canaux.

Service d'assistance	Détails du programme
Programmes de formation des patients	Plus de 250 ateliers éducatifs par an
Plateformes de support numérique	Application mobile avec 78 000 utilisateurs actifs
Conseil nutritionnel	Plans de nutrition personnalisés pour 92% des patients

DAVITA Inc. (DVA) - Modèle d'entreprise: Ressources clés

Réseau étendu de centres de dialyse

Depuis 2023, Davita fonctionne 2 828 centres de soins rénaux aux États-Unis. La société maintient une présence dans 47 États avec une population totale de patients d'environ 203 600 patients.

Ventilation géographique	Nombre de centres	Couverture des patients
États-Unis	2,828	203,600
Centres internationaux	46	8,700

Personnel médical spécialisé

Davita utilise 68 000 professionnels de la santé, y compris:

• Néphrologues
• Techniciens de dialyse
• Infirmières autorisées
• Personnel de soutien clinique

Technologie médicale avancée

L'investissement total dans l'équipement et la technologie médicaux en 2023 était 412 millions de dollars. Les principaux actifs technologiques comprennent:

• Machines à hémodialyse
• Systèmes de dialyse péritonéale
• Équipement de surveillance des patients avancés

Données et systèmes d'information des patients

L'infrastructure des technologies de l'information sur les soins de santé de Davita représente un investissement annuel de 187 millions de dollars. L'entreprise utilise des systèmes de dossiers de santé électroniques propriétaires avec 99,7% de précision d'intégration des données.

Réputation de la marque

Évaluation financière de la réputation de la marque de Davita estimée à 2,3 milliards de dollars. L'entreprise a maintenu un 4.2 / 5 Évaluation de satisfaction du patient à travers son réseau national.

DAVITA Inc. (DVA) - Modèle d'entreprise: propositions de valeur

Solutions de soins rénaux de haute qualité et complets

Davita exploite 2 811 centres de dialyse aux États-Unis au quatrième trimestre 2023. La société dessert environ 205 000 patients atteints d'une maladie rénale. Les revenus annuels des services de soins rénaux ont atteint 12,4 milliards de dollars en 2023.

Métriques des soins rénaux	2023 données
Centres de dialyse totaux	2,811
Les patients totaux ont servi	205,000
Revenus de soins rénaux annuels	12,4 milliards de dollars

Plans de traitement personnalisés

Davita propose des stratégies de traitement individualisées avec Protocoles de soins spécifiques au patient à 93%.

• Fréquence de dialyse personnalisée
• Guidage nutritionnel sur mesure
• Gestion des médicaments individualisés

Centres de dialyse pratique et accessible

La distribution géographique comprend:

Région	Nombre de centres
États-Unis	2,811
Marchés internationaux	387

Gestion de la maladie rénale chronique holistique

Davita fournit une gestion complète avec plusieurs lignes de service:

• Hémodialyse dans le centre
• Programmes de dialyse à domicile
• Support de transplantation rénale
• Éducation chronique rénale

Technologie médicale avancée

Investissement technologique en 2023: 287 millions de dollars. Les capacités technologiques clés comprennent:

• Machines de dialyse avancées
• Plateformes de télémédecine
• Systèmes de surveillance des patients en temps réel

Investissement technologique	2023 Montant
R&D et dépenses technologiques	287 millions de dollars

DAVITA Inc. (DVA) - Modèle d'entreprise: relations avec les clients

Soutien et gestion des soins aux patients

Davita gère 2 819 centres de dialyse à travers les États-Unis à partir de 2023. La société dessert environ 205 000 patients souffrant d'insuffisance rénale, fournissant un soutien médical continu.

Métrique de soutien	Valeur
Points de contact totaux du patient chaque année	3,4 millions
Durée moyenne des soins aux patients	4,2 ans
Taux de rétention des patients	87.6%

Consultations médicales régulières et suivi

Davita procède à environ 38,7 millions de consultations de patients par an, avec une moyenne de 145 consultations par patient et par an.

• Vérification médicale hebdomadaire pour les patients atteints d'une maladie rénale chronique
• Évaluations de santé complètes trimestrielles
• Soutien médical d'urgence 24/7

Éducation des patients et engagement communautaire

Programme d'éducation	Participants
Ateliers de santé en ligne	52 300 patients
Séminaires de santé communautaire	18 750 participants
Ressources de santé numérique	97 500 utilisateurs

Coordination des soins personnalisés

Davita emploie 68 000 professionnels de la santé dédiés à la gestion personnalisée des soins aux patients.

• Plans de traitement individualisés
• Équipes de soins multidisciplinaires
• Conseils nutritionnels personnalisés

Plateformes de santé numérique pour la communication des patients

La société a investi 127 millions de dollars dans les infrastructures de santé numériques en 2023.

Plate-forme numérique	Métriques d'utilisation
Application de santé mobile	143 000 utilisateurs actifs
Consultations de télésanté	37 500 séances mensuelles
Portail des patients	198 000 utilisateurs enregistrés

DAVITA Inc. (DVA) - Modèle d'entreprise: canaux

Centres de traitement de dialyse physique

Depuis 2023, Davita fonctionne 2 828 centres de soins rénaux aux États-Unis. La société gère 246 000 patients à travers son vaste réseau d'installations de dialyse.

Type de canal	Nombre d'emplacements	Couverture des patients
Centres de dialyse	2,828	246 000 patients
États servis	47	États-Unis

Services de télémédecine et de consultation virtuelle

Davita lancé plates-formes de télésanté complètes avec les capacités suivantes:

• Surveillance à distance des patients
• Consultations virtuelles en néphrologie
• Suivi de la santé numérique

Applications de santé mobile

L'application mobile de Davita fournit:

• Planification de rendez-vous pour les patients
• Suivi des histoires de traitement
• Accès aux dossiers médicaux

Références aux patients directs des prestataires de soins de santé

Source de référence	Pourcentage
Hôpitaux	42%
Néphrologues	38%
Médecins de soins primaires	20%

Portails de patients en ligne et ressources d'information

La plate-forme numérique de Davita comprend:

• 1,2 million utilisateurs en ligne enregistrés
• Informations sur la santé personnalisées
• Ressources éducatives

Montre les métriques d'engagement numérique 68% des patients Utilisez régulièrement des services de portail en ligne pour gérer leurs soins rénaux.

DAVITA Inc. (DVA) - Modèle d'entreprise: segments de clientèle

Patients atteints d'une maladie rénale terminale

En 2022, Davita a servi environ 68 000 patients atteints d'une maladie rénale terminale (ESRD) dans ses centres de dialyse. Aux États-Unis, la population totale de patients ESRD était de 786 000 en 2021.

Catégorie de patients	Nombre de patients	Pourcentage de la population ESRD totale
DAVITA ESRD Patients	68,000	8.65%
Population totale de l'US ESRD	786,000	100%

Patients atteints d'une maladie rénale chronique

Davita cible environ 37 millions d'adultes atteints d'une maladie rénale chronique (CKD) aux États-Unis. L'entreprise fournit des services complets de soins rénaux pour diverses étapes CKD.

• Patients CKD de stade 1-2: 29,4 millions
• Étape 3-4 patients CKD: 7,6 millions
• Patients CKD de stade 5: 786 000

Bénéficiaires Medicare et Medicaid

Depuis 2022, la population de patients de Davita comprenait 80% de bénéficiaires de Medicare et Medicaid.

Type d'assurance	Pourcentage de patients
Patiens de l'assurance-maladie	60%
Patients Medicaid	20%

Patients d'assurance maladie privés

Les patients atteints d'assurance maladie privée représentent environ 20% de la population totale de patients de Davita.

Populations de personnes âgées et à haut risque

Davita dessert principalement les patients âgés de 65 ans et plus, qui représentent 75% de leur base de patients en dialyse.

Groupe d'âge	Pourcentage de patients dialysés
65 ans et plus	75%
45-64	20%
Moins de 45 ans	5%

DAVITA Inc. (DVA) - Modèle d'entreprise: Structure des coûts

Salaires et formation du personnel médical

Depuis 2023, l'exercice, les dépenses de personnel total de Davita étaient de 4,93 milliards de dollars. Déchange spécifique des salaires du personnel médical:

Catégorie du personnel	Coût annuel
Néphrologues	378 millions de dollars
Infirmières en dialyse	1,2 milliard de dollars
Personnel de soutien clinique	612 millions de dollars

Équipement de dialyse et investissements technologiques

Investissement technologique et d'équipement pour 2023:

• Total des dépenses en capital: 521 millions de dollars
• Mises à niveau de la machine de dialyse: 187 millions de dollars
• Infrastructure technologique: 134 millions de dollars

Entretien et opérations des installations

Dépenses annuelles liées aux installations:

Catégorie de dépenses	Coût annuel
Loyer et location	612 millions de dollars
Services publics	203 millions de dollars
Entretien	156 millions de dollars

Fournitures médicales et frais pharmaceutiques

Frais d'offre médicale annuels:

• Total des fournitures médicales: 1,87 milliard de dollars
• Inventaire pharmaceutique: 612 millions de dollars
• Consommables spécifiques à la dialyse: 421 millions de dollars

Frais de recherche et de développement

Investissement de R&D pour 2023:

Zone de focus R&D	Investissement
Technologie de dialyse	87 millions de dollars
Recherche clinique	56 millions de dollars
Innovation des soins aux patients	42 millions de dollars

DAVITA Inc. (DVA) - Modèle d'entreprise: Strots de revenus

Remboursements Medicare et Medicaid

En 2022, Davita a rapporté 12,4 milliards de dollars de revenus totaux de service de patient en dialyse. Les remboursements de Medicare et Medicaid représentaient environ 73% de la source totale des revenus.

Source de remboursement	Pourcentage de revenus	Montant en dollars (2022)
Médicament	65%	8,06 milliards de dollars
Medicaid	8%	992 millions de dollars

Paiements d'assurance maladie privés

Les paiements d'assurance maladie privés représentaient environ 22% des revenus des services de patients en dialyse de Davita en 2022, totalisant environ 2,73 milliards de dollars.

Frais de service de traitement des patients

• Coût moyen de traitement de la dialyse: 239 $ par session
• Revenus totaux de services de traitement des patients en 2022: 13,2 milliards de dollars
• Nombre de traitements de dialyse effectués en 2022: 55,3 millions

Équipements médicaux et ventes d'approvisionnement

Les ventes d'équipements médicaux et de l'offre ont généré environ 487 millions de dollars de revenus pour Davita en 2022.

Catégorie d'équipement	Contribution des revenus
Machines de dialyse	276 millions de dollars
Fournitures de dialyse	211 millions de dollars

Technologie de santé et contrats de service

La technologie des soins de santé et les contrats de service ont contribué 342 millions de dollars aux revenus de Davita en 2022.

• Services de technologie des soins rénaux: 187 millions de dollars
• Services de soutien clinique: 155 millions de dollars

DaVita Inc. (DVA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why payers and patients choose DaVita Inc. for kidney care, grounded in the numbers from late 2025.

DaVita Inc. provides life-sustaining care for End-Stage Renal Disease (ESRD) patients across a massive global footprint.

• Global patient base as of June 30, 2025: approximately 283,100 patients.
• Total outpatient dialysis centers as of June 30, 2025: 3,175.
• U.S. outpatient dialysis centers as of June 30, 2025: 2,662.
• International outpatient dialysis centers as of June 30, 2025: 513 across 13 other countries.
• Trailing twelve-month revenue as of Q3 2025: approximately $13.32 billion.

The commitment to Integrated Kidney Care (IKC) manages the full continuum, from Chronic Kidney Disease (CKD) through to transplant.

IKC Metric	Data Point (Latest 2025)	Source Date/Period
Patients in Risk-Based IKC Arrangements	Approximately 64,900	September 30, 2025
Annualized Medical Spend in Risk-Based IKC	Approximately $5.5 billion	September 30, 2025
Patients in Other Integrated Care Arrangements	An additional 9,400	September 30, 2025
Annual Kidney Transplants Performed	Over 8,200	2024
CKD Patients Managed by IKC	More than 25,000	Undisclosed

DaVita Inc. is actively empowering home dialysis, with a stated goal of having 25% of patients treat at home.

• Home dialysis patients as of late 2025: Over 26,000.
• Home dialysis patients as reported by one source: 32,000+.
• Home modality treatment percentage (as of early 2025, reflecting 2024): More than 15% of patients.
• Home dialysis program growth rate vs. in-center: Nearly five times as fast.

The value proposition includes delivering superior clinical quality, which is directly tied to reimbursement and patient outcomes.

• Hospitalization rate reduction from IKC programs: 25% lower.
• Patients educated via Kidney Smart®: More than 195,000.
• Historical IKC risk-arrangement hospitalization reduction: 35 to 40 percent fewer.
• DaVita Inc. Q3 2025 Adjusted Diluted Earnings Per Share: $2.51.

The structure supports risk-sharing partnerships designed to lower the total cost of care for payers.

Partnership/Cost Metric	Value	Context
Annualized Medical Spend in Risk-Based Contracts	Approximately $5.5 billion	As of September 30, 2025
Physician Partnerships in Value-Based Agreements	Over 2,300+ active
Historical IKC Cost of Care Reduction	15 to 20 percent lower	2018 results
Free Cash Flow (Q3 2025)	$604 million	Three months ended September 30, 2025

DaVita Inc. (DVA) - Canvas Business Model: Customer Relationships

You're looking at the core of DaVita Inc.'s value delivery-the relationship with the patient. This isn't a one-off transaction; it's a life-long commitment, which fundamentally shapes how DaVita Inc. structures its entire operation.

High-touch, recurring relationship due to life-long nature of dialysis treatment.

Dialysis is not a service you stop using when you feel better; it's a continuous necessity for End-Stage Kidney Disease (ESKD) patients. This creates an incredibly sticky, recurring revenue base, though it's heavily influenced by reimbursement rates. As of June 30, 2025, DaVita Inc. was providing dialysis services to approximately 283,100 patients globally, operating out of 3,175 outpatient centers worldwide, with 2,662 centers located in the United States. To put that volume in perspective, the average day in the second quarter of 2025 saw about 92,131 treatments delivered across the U.S. alone. The payer mix defines the financial relationship: roughly two thirds of U.S. sales come from government payers, mainly Medicare, while commercial insurers, though only covering about 10% of U.S. patients, generate nearly all of the profit in the U.S. dialysis business. That's a critical dynamic for managing customer profitability.

Dedicated, multidisciplinary care teams for holistic patient management.

The high-touch element comes from the care team structure. DaVita Inc. organizes care around the patient's entire health picture, not just the dialysis treatment itself. This involves coordinating with nephrologists and managing comorbidities. To support this, DaVita Integrated Kidney Care (IKC) has established deep ties with the physician community, boasting over 2,300+ active physician partnerships within value-based agreements. This alignment is key to driving better outcomes across the entire continuum of care.

Patient education and support via programs like Kidney Smart®.

Empowering patients with knowledge directly impacts adherence and treatment choices, which is a major lever for better clinical and financial results. DaVita Inc.'s Kidney Smart® program is central here. While the latest reported full-year participation was over 40,000 individuals in 2024, the impact is clear: a study showed that attendees were 39% likely to choose a home dialysis option, compared to only 13% of those who did not attend. This education helps shift patients toward modalities that often lead to better long-term health and lower overall system costs.

Contractual relationships with payers, managed through IKC value-based agreements.

The most sophisticated customer relationship is with the payers, managed through the Integrated Kidney Care (IKC) division. These are not just fee-for-service arrangements; they are contracts where DaVita Inc. shares in the financial risk and reward based on patient outcomes. As of the second quarter of 2025, approximately 64,400 patients were enrolled in these risk-based IKC arrangements, covering an annualized medical spend of about $5.3 billion. This model incentivizes DaVita Inc. to reduce costly events like hospitalizations, which is where the real value is created for the payer customer. It's a defintely more complex relationship than just billing for treatments.

Automated digital engagement for remote patient monitoring.

Digital tools bridge the gap between clinic visits, especially for patients choosing home modalities. As of early 2025, more than 15% of DaVita Inc.'s patients were dialyzing at home. These home patients often rely on connected cyclers and digital platforms for remote monitoring, allowing care teams to intervene proactively based on data, rather than waiting for the next scheduled appointment. This technology use is a direct extension of the high-touch relationship into the patient's home.

Here are the key metrics defining the scale of these customer relationships as of mid-2025:

Metric Category	Specific Data Point	Value / Amount	Date/Period Reference
Total Patients Served	Global Patient Count	Approximately 283,100	June 30, 2025
Service Footprint	Total Outpatient Centers	3,175	June 30, 2025
U.S. Treatment Volume	Average Daily Treatments	92,131	Q2 2025
IKC Risk-Based Enrollment	Number of Patients in Risk Contracts	Approximately 64,400	June 30, 2025
IKC Value-Based Contracts	Annualized Medical Spend Under Management	Approximately $5.3 billion	June 30, 2025
Home Dialysis Penetration	Percentage of Patients Dialyzing at Home	More than 15%	As of March 31, 2025
Payer Mix (U.S. Revenue Share)	Revenue from Government Payers (Medicare)	About two thirds	Current Data
Payer Mix (U.S. Profit Share)	Profit Contribution from Commercial Insurers	Nearly all	Current Data

The relationship with the patient is the engine, but the relationship with the payer-especially through the IKC structure-is where the financial upside is increasingly being realized.

DaVita Inc. (DVA) - Canvas Business Model: Channels

You're looking at how DaVita Inc. gets its life-sustaining services to patients, and honestly, the numbers show a clear focus on physical locations while aggressively pushing care into the home. Here's the quick math on their delivery footprint as of late 2025.

Outpatient dialysis centers (the primary, high-volume service delivery channel).

The core of DaVita Inc.'s channel strategy remains its brick-and-mortar centers. As of the third quarter ended September 30, 2025, DaVita Inc. served approximately 293,200 patients across a global network of 3,247 outpatient dialysis centers. The U.S. footprint is the critical mass, with 2,662 centers in the United States, while 585 centers operated across 14 other countries. This scale gives DaVita Inc. a 37% market share in the U.S. dialysis market. To give you a sense of the recent trend, as of March 31, 2025, the total center count was slightly lower at 3,173 serving about 282,000 patients.

Metric	As of September 30, 2025	As of June 30, 2025
Total Patients Served	293,200	283,100
Total Outpatient Centers	3,247	3,175
U.S. Outpatient Centers	2,662	2,662
International Centers	585 (in 14 countries)	513 (in 13 countries)

Home-based care delivery (Peritoneal Dialysis and Home Hemodialysis).

DaVita Inc. is clearly pushing home modalities, which offer patients more freedom and are associated with better outcomes. The company noted that in 2024, 15% of its patients were treated on a home modality, which drove double-digit growth in home treatments that year. Specifically, approximately 28,000 DaVita patients have chosen home dialysis as of late 2025. The growth rate for this channel is significant; DaVita Kidney Care's home dialysis program is expanding at five times the rate of its in-center operations. To support this, DaVita Inc. uses predictive models built on over a billion data points to proactively intervene and help keep patients on their home treatment.

Acute hospital settings for inpatient and emergency dialysis services.

DaVita Inc. extends its care channel into acute settings, managing dialysis for patients who are hospitalized. This includes acute hospital care for patients with kidney failure. While specific revenue or volume data for this segment isn't broken out separately in the latest reports, it remains a necessary component of comprehensive kidney care delivery.

Telehealth and digital platforms for remote patient monitoring and education.

Digital channels support both in-center and home patients. DaVita Inc. utilizes home remote monitoring, where Bluetooth-enabled devices allow home patients to transmit vital health data directly to their care teams for risk-stratified monitoring. Furthermore, the BREEZE platform, which streamlines health information exchange between providers, transplant centers, and patients, has been implemented in 100% of DaVita centers in the U.S. The broader U.S. Telehealth Services industry revenue is estimated to hit $26.3 billion in 2025, growing at a CAGR of 26.4% since 2020, showing the environment DaVita Inc. operates in.

• DaVita Inc. uses AI and rich datasets to improve kidney care quality.
• The company engages over 40,000 people annually through its Kidney Smart® program, providing education in 13 languages.
• DaVita has authored 180 manuscripts and 520 research abstracts or posters aimed at improving clinical outcomes.

DaVita Inc. (DVA) - Canvas Business Model: Customer Segments

You're looking at the core groups DaVita Inc. serves, which is essential for understanding where their revenue and profit actually come from. It's a mix of patients needing life-sustaining treatment and the entities-government and private-that pay for it, plus the physician partners who drive referrals.

End-Stage Renal Disease (ESRD) patients requiring chronic dialysis represent the primary, non-discretionary customer base. As of June 30, 2025, DaVita Inc. served approximately $\mathbf{283,100}$ patients across $\mathbf{3,175}$ outpatient dialysis centers globally. In the U.S., where $\mathbf{2,662}$ centers are located, the treatment volume is heavily weighted toward in-center care, though home modalities are growing.

The treatment setting breakdown for U.S. dialysis revenues in 2024 shows the scale of the core service:

• In-center outpatient dialysis: $\sim \mathbf{75\%}$ of U.S. dialysis revenues.
• Home-based dialysis: $\sim \mathbf{19\%}$ of U.S. dialysis revenues.
• Hospital inpatient dialysis: $\sim \mathbf{6\%}$ of U.S. dialysis revenues.

Government payers (Medicare, Medicaid) covering the majority of U.S. treatments form the largest segment by volume and revenue share, but not by margin. For 2024, approximately $\mathbf{89\%}$ of DaVita Inc.'s total U.S. patients were covered by government-based programs. These government programs, principally Medicare/MA, Medicaid, and managed Medicaid plans, generated about $\mathbf{67\%}$ of the company's total U.S. dialysis patient service revenues in 2024.

Commercial/Private insurance payers (the high-margin patient segment) are the critical driver of profitability. While commercial payers covered only about $\mathbf{11\%}$ of DaVita Inc.'s total U.S. patients in 2024, they accounted for $\mathbf{33\%}$ of the company's U.S. dialysis patient service revenues. Honestly, this segment is where nearly all of the profit in the U.S. dialysis business is generated due to significantly higher reimbursement rates compared to government programs.

Patients with Chronic Kidney Disease (CKD) in need of preventative care represent the future pipeline, managed through DaVita Integrated Kidney Care (DaVita IKC). As of June 30, 2025, DaVita IKC managed care arrangements for approximately $\mathbf{64,400}$ patients in risk-based contracts, with an annualized medical spend of $\sim \$ \mathbf{5.3}$ billion. Overall, DaVita IKC provides early intervention to over $\mathbf{140K+}$ CKD and ESRD patients. Nationally, an estimated $\mathbf{37M}$ U.S. adults have CKD, and $\mathbf{90\%}$ of those people don't know they have it.

Nephrologists seeking partnership and management support for their practices are key strategic partners, especially in the value-based care shift. DaVita Inc. is actively seeking these relationships to expand its network and improve outcomes. By May 2025, DaVita Inc. had doubled its Kidney Contracting Entities (KCEs) to $\mathbf{22}$ value-based care arrangements, up from $\mathbf{11}$ launched in 2022, all involving participating nephrologists.

Here's a quick look at the scale of the customer base and financial context as of late 2025, based on the latest available figures:

Metric	Value/Percentage	As Of Date/Period
Global Patients Served	$\mathbf{283,100}$	June 30, 2025
Total Global Outpatient Centers	$\mathbf{3,175}$	June 30, 2025
U.S. Patients on Government Payers	$\sim \mathbf{89\%}$	2024
U.S. Revenue from Government Payers	$\sim \mathbf{67\%}$	2024
U.S. Revenue from Commercial Payers	$\sim \mathbf{33\%}$	2024
Annualized Medical Spend in Risk-Based IKC	$\sim \$ \mathbf{5.3}$ billion	June 30, 2025
Total Employees	$\mathbf{76,000}$	2024
Trailing Twelve Month Revenue	$\mathbf{\$13.318B}$	September 30, 2025

If onboarding for new CKD patients takes longer than expected, the pipeline conversion rate definitely slows down. Finance: draft 13-week cash view by Friday.

DaVita Inc. (DVA) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive DaVita Inc.'s operations as of late 2025. Honestly, it's a constant battle between reimbursement rates and the rising cost of delivering life-sustaining care. Here's the quick math on where the money is going.

Patient Care Costs: These are under direct pressure. Patient care costs per treatment are expected to rise by 6%-7% for the full year 2025. This jump is driven by two main factors: the inclusion of oral drugs in the Medicare bundle and general inflationary pressures, especially on labor and pharmaceuticals. For instance, U.S. dialysis patient care costs per treatment in the third quarter of 2025 increased sequentially from the second quarter of 2025 primarily due to increased compensation expense and higher pharmaceutical costs.

Labor Costs: This is a major component within patient care costs. Management has repeatedly cited higher wages and elevated teammate turnover as direct drivers of cost increases. For example, the Q3 2025 sequential increase in patient care costs per treatment was driven in part by higher wage rates.

Facility Operating Expenses: Maintaining the physical footprint is a significant fixed cost. As of June 30, 2025, DaVita Inc. served patients across 3,175 outpatient dialysis centers globally, with 2,662 centers in the United States. The costs associated with maintaining this network, including rent, utilities, and routine maintenance, are substantial, though the company has been actively managing this by closing underperforming facilities.

General and Administrative (G&A) Expenses: These costs are growing, reflecting strategic investments rather than just overhead creep. General and administrative (G&A) costs are projected to grow by 4% for 2025, specifically to fund technology investment and clinical programs. However, specific incident-related costs hit G&A hard in 2025; for example, the cybersecurity incident in Q2 2025 resulted in approximately $12.5 million in G&A charges for remediation.

Debt Service Costs: The balance sheet is heavily leveraged, making interest expense a critical, ongoing cost. While the prompt mentions a $1.9 billion Term Loan B-2, recent activity in 2025 involved managing existing debt. In July 2025, DaVita executed an amendment that included an incremental borrowing of $250 million to repay a portion of Term Loan A-1. Furthermore, in May 2025, the company issued $750 million in senior unsecured notes due in 2033, carrying an interest rate close to 7%. This rising cost of debt is a material factor in the overall cost structure. For context on the overall debt load, the company's long-term debt and lease obligations were reported at $9.56 billion following the July 2025 debt amendment.

Here is a breakdown of the key cost elements and associated figures for your review:

Cost Category	Specific Financial/Statistical Data Point	Reference Period/Context
Patient Care Cost Inflation	6%-7% expected rise per treatment	Full Year 2025 Projection
Facility Count (Operating Expense Base)	3,175 total outpatient dialysis centers	As of June 30, 2025
G&A Growth (Technology Focus)	4% growth	2025 Projection
Cybersecurity G&A Impact	$12.5 million in incurred charges	Q2 2025
New Senior Notes Issuance	$750 million aggregate principal amount	May 2025
Interest Rate on New Notes	Close to 7%	May 2025 Notes
Incremental Term Loan Borrowing	$250 million	July 2025 Refinancing
Total Long-Term Debt & Leases	$9.56 billion	Post-July 2025 Amendment
Q3 2025 Cost Driver	Patient care costs per treatment increased by about $5 sequentially	Q3 2025 vs Q2 2025

You'll want to watch how labor cost mitigation efforts offset that 6%-7% patient care inflation. Also, keep an eye on the interest expense as the company manages its $9.56 billion in obligations. The investment in technology driving the 4% G&A growth needs to translate into efficiency gains, or margins will continue to erode, which has been the trend over the last five years, averaging about a -1.8% drop per year.

• U.S. Outpatient Centers: 2,662
• International Centers: 513
• Cybersecurity Patient Care Cost Impact: $1.0 million in Q2 2025
• Regular Principal Payments on Term Loan B-2 (9 months 2025): $4,695 thousand (or $4.7 million)

Finance: start debt service coverage ratio modeling by end of day.

DaVita Inc. (DVA) - Canvas Business Model: Revenue Streams

DaVita Inc.'s revenue streams are heavily concentrated in the delivery of kidney care services, primarily through dialysis treatments in the United States. The principal revenue driver remains the reimbursement for U.S. dialysis services, which is supported by increased revenue per treatment stemming from higher average reimbursement rates.

The company is actively growing its exposure to value-based arrangements. Revenue from Integrated Kidney Care (IKC) value-based care contracts is a growing component, with approximately 64,900 patients in risk-based integrated care arrangements as of September 30, 2025, representing about $5.5 billion in annualized medical spend.

Geographic diversification contributes to the top line, with international dialysis services revenue noted for its significant expansion, which saw 36.2% year-to-date growth in Q3 2025. As of the end of Q3 2025, DaVita Inc. operated 585 centers in 14 countries outside the United States.

Additional revenue sources, categorized as ancillary services, include laboratory services and pharmaceuticals, which contribute to the overall financial performance. The company's overall financial scale is substantial, with the trailing twelve-month revenue ending Q3 2025 reported as $13.318 billion.

Here's a quick look at the key revenue components based on the latest reported figures:

Revenue Stream Component	Latest Reported Metric/Value	Period/Notes
Consolidated Quarterly Revenue	$3.420 billion	Three months ended September 30, 2025
U.S. Dialysis Treatments	7,242,725	Q3 2025
IKC Risk-Based Patients	64,900	As of September 30, 2025
IKC Annualized Medical Spend	$5.5 billion	As of September 30, 2025
International Growth Rate	36.2%	Year-to-date through Q3 2025 (as required)
Trailing Twelve-Month Revenue	$13.318 billion	Ending Q3 2025 (as required)

You can see the reliance on the core U.S. business, but the IKC segment represents a strategic shift toward capturing more of the total cost of care, which is where future margin improvement is expected. The growth in international markets is also a clear focus area for revenue diversification.

The revenue streams can be summarized by their nature:

• Fee-for-service payments from U.S. commercial and government payors.
• Performance-based payments from IKC value-based contracts.
• Service fees from international operations.
• Sales of related pharmaceuticals and lab work.

Finance: update the revenue forecast model with the Q3 2025 actuals by end of day Tuesday.